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Abstract
Background: MLPA method is a potentially useful semi-quantitative method to detect copy
number alterations in targeted regions. In this paper, we propose a method for the normalization
procedure based on a non-linear mixed-model, as well as a new approach for determining the
statistical significance of altered probes based on linear mixed-model. This method establishes a
threshold by using different tolerance intervals that accommodates the specific random error
variability observed in each test sample.
Results: Through simulation studies we have shown that our proposed method outperforms two
existing methods that are based on simple threshold rules or iterative regression. We have
illustrated the method using a controlled MLPA assay in which targeted regions are variable in copy
number in individuals suffering from different disorders such as Prader-Willi, DiGeorge or Autism
showing the best performace.
Conclusion: Using the proposed mixed-model, we are able to determine thresholds to decide
whether a region is altered. These threholds are specific for each individual, incorporating
experimental variability, resulting in improved sensitivity and specificity as the examples with real
data have revealed.
Background
With the recent technological advances, different genome-
wide studies have uncovered an unprecedented number
of structural variants in the human genome [1-7], mainly
in the form of copy number variations (CNVs). As much
as 12% of the human genome has been reported to be var-
iable among different individuals [6]. The important
number of genes and other regulatory elements encom-
passed by those variable regions, makes it very likely for
them to have functional and, ultimately, phenotypical
consequences [8,9]. In fact, several publications have
already correlated the number of copies of different genes
with different degrees of disease predisposition [10-12].
Therefore, the identification of DNA copy number is
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human diseases.
Several techniques and platforms have been developed for
genome-wide analysisi of DNA copy number, such as
array-based comparative genomic hybridization (aCGH).
The goal of the analysis of DNA copy number data using
this approach is to partition the whole genome into seg-
ments where copy numbers changes between contiguous
segments may be present. The ability of aCGH to discern
between different number of copies is very limited, thus
different kinds of techniques have been developed for tar-
geted, and more precise, analyses of genomic regions.
Multiplex Ligation-dependent Probe Amplification
(MLPA) [13] is one of the most used technologies among
other existing ones such us Quantitative Multiplex PCR of
Short Fluorescent (QMPSF) [14,15] or Multiplex Amplifi-
able Probe Hybridization (MAPH) [16].
MLPA is a recently developed semi-quantitative method
that aims to detect copy number alterations at the
genomic level (gains or loses) in a test DNA with respect
to a control. Due to its low cost, reliability and ease of
implementation it has become very popular both as a
research and a diagnostic tool. After hybridization, liga-
tion and multiplex amplification of specific probes target-
ing different genomic regions, the probes are
electrophoresed and analyzed using a DNA analyzer [13].
Each specific probe migrates according to its molecular
weight and the resulting pherograms show specific peaks
that correspond to each probe (Figure 1). Relative dosage
information can be obtained after the comparison of peak
intensities (height or area) of the different probes between
test and control samples.
Due to the variation of PCR efficiencies across probes (due
to their different size and nature) and across samples, a
normalization method is needed before comparing dos-
age quotients. This step is crucial because the variation in
experimental conditions may lead to differences of meas-
ured values between samples, thus hampering the correct
interpretation of results. After normalization, which elim-
inates possible differences introduced during the experi-
mental process, we aim to find biological differences in
gene dosage (copy numbers). That is, the normalization
tries to minimize the amount of systematic non-biological
variation among samples. Different normalization meth-
ods have been used for analyzing MLPA data. The most
common method divides each intensity by the sum of all
intensities in each sample (see, for instance [17] and
[18]). Other alternative approaches are based on regres-
sion methods that account for the amplification decay of
larger probes. One of such regression methods uses inter-
nal control probes [19], while the another normalizes
intensities based upon the statistically most probable
median peak intensities using a median filter [20]. Other
authors suggest to normalize peak intensities by using 4
separate peak groups according to increasing frament sizes
ot the peaks (see [21] for further details). Finally, a similar
approach using the mean intensity of control probes
inside a normalization group as the dividing factor was
considered in [22].
After an intensity normalization, the next key point is the
determination of genes that are significantly altered. As an
example, the peak intensity of exon 13 in Figure 1 seems
to be lower in patient than in control indicating a dele-
tion. Again, different approaches have been used to find
probes that are altered. In this work we are considering
ratio- [18,23] and regression-based [19,20] methods. In
both approaches, the basis for the analysis is the compar-
ison among normalized peak intensities from patient and
control samples using a dosage ratio. In the ratio-based
approach, deletions and duplications are given as outliers
from the data set after defining a "biological" threshold
(i.e. in a diploid genome, two copies exists of each gene).
We assume that the simplest, most likely scenario, is an
heterozygous gain or a loss of the material, under which
ideal ratio values of 1.5 and 0.5 are expected, respectively.
In such a simple scenario, and taking into account experi-
mental noise, it is generally accepted in the literature that
values below 0.7 and above 1.33 are indicative of loss and
gain of a genetic material, respectively [13,18]. The regres-
sion-based approach is based on fitting several linear
regression models, considering the normalized peak
intensity of a given patient as the dependent variable and
the normalized peak intensities of the mean control sam-
ple as independent variables. Another method based on
taking into account the individual noise for each probe
(i.e., standard deviation) for all control samples is consid-
ered in [24].
Both the ratio- and regression-based methods have gen-
eral drawbacks. The ratio-based approach always consid-
ers the same gain/loss threshold without taking into
account the different variability among experiments and
among probes. On the other hand, although the regres-
sion-based approaches solve this problem, fitting regres-
sion models without considering that the independent
variable (normalized peak intensity in controls) is also
subject to error may lead to wrong conclusions. In addi-
tion, the regression method uses confidence intervals for
predictions which are built under the normal theory. The
normality assumption may be untenable, particularly
because of the limited amount of control probes that are
typically used in routine experiments (< 10 probes).
Finally, none of these procedures considers replicates for
each individual, reducing information by averaging the
replicate values.Page 2 of 15
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methods to deal with the normalization and the discovery
of alterations when analyzing MLPA data. Our approach
is based on both nonlinear (normalization procedure)
and linear (to determine alteration) mixed models. The
main advantages of our methods are: (1) the variation
among individuals is modelled explicitly using a random
effect; and (2) the replicates may be easily incorporated in
the model. The deletions and duplications will be deter-
mined using tolerance intervals. We validate and compare
our methods with the existing methods using a controlled
experiment. We evaluate the presence of gains and loses in
a set of DNAs from normal individuals and individuals
affected by known genetic disorders. The probemix we
used included probes of single copy number regions
located both inside and outside of the genomic disorder
regions. A total of 30 samples, including 24 controls and
6 patients, were analyzed blindly.
Results
Simulation study
In this section, we investigate the performance of the two
existing methods and our proposed approach through a
number of simulations. We simulated an hypothetical
assay with 45 probes. We also simulated internal control
probes (i.e. non-altered) to be used in the iterative regres-
sion approach by setting σγ = 0. Two different scenarios
were simulated in order to investigate the performance of
Example of a deletion in an MLPA assayFigure 1
Example of a deletion in an MLPA assay. Panels A and B show pherograms corresponding to the electrophoresis of an 
MLPA assay. In the Y-asix are depicted the intensity signals (peak heights) for each probe that are depicted in the X-axis 
according to their length (probe size). Peaks marked with a C correspond to control probes and peaks numbered from 1 
through 24 correspond to region-specific probes. Panel A corresponds to a normal individual, while panel B corresponds to an 
individual with a deletion at probe #13 as visible by the reduced peak intensity in this pherogram.Page 3 of 15
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10% and 20% of the 45 probes. Finally, the ratios of the
rest of probes were simulated as altered (gains or loses)
depending on a different percentages: 5%, 10%, 20% and
50% of the probes. These values were generated from a
normal distribution under different scenarios varying
between probe variability (σβ ∈ {0.2, 0.4, 0.6}), probe-
test variability (σγ ∈ {0.2, 0.4, 0.6, 1.0, 1.5, 4.0}) and
within-probe or random variability (σε ∈ {0.05, 0.08}).
We simulated 3 replicates of each peak intensity for test
and control samples. Note that the average of these repli-
cates were considered in the case of using threshold and
REX-MLPA approaches. We summarized our simulations
by computing the mean number of altered probed simu-
lated in each run, the empirical type-I error and the empir-
ical power to detect gains and loses. These results are
based on 1,000 simulations.
Tables 1 and 2 show the results for the case of having 10%
of true altered probes when 10% and 20% of probes have
been generated as a internal control probes, respectively.
The results for the REX-MLPA method were based on
building confidence limits at 99% at each iteration.
Regarding the empirical type-I error, the REX-MLPA
approach usually overestimate the expected 5%, while the
threshold method clearly underestimates type-I error
since in all simulations the simulated type-I error was
closer to 0% (results omitted in the tables). On the other
hand, the probe-specific model shows a good perform-
ance. As expected, the power of the three methods
increases when the probe-test variability increases. That is,
the power depends on the size effect of those altered
probes. In general, the probe-specific mixed-model out-
performs both REX-MLPA and threshold approaches. The
threshold approach is clearly underpowered for those
cases in which the magnitude of the effect is not large
enough. Finally, the same pattern is observed when the
random variability is increased (e.g. within-probe varia-
bility) but showing lower power. The simulation results
for the case of having 5%, 20% and 50% of true altered
probes showed similar behaviour and they can be found
in the Additional file 1.
Validation study
In order to validate our proposed method, and compare
its performace with those of the existing methods, we
have designed a controlled MLPA probemix in which we
have included 34 different oligonucleotides, correspond-
ing to 16 different targeted regions with single copy
number in normal individuals. Eight of the targeted
regions are variable in copy number in individuals suffer-
ing from different genomic disorders (see Table 3). A total
of 30 DNAs from different individuals were assayed in
triplicate in the study. 24 of the DNAs came from unre-
lated HapMap individuals (i.e. normal general popula-
tion), 2 DNAs from Prader-Willi syndrome patients
(15q11-q13 deletion), 2 DNAs from DiGeorge syndrome
patients (22q11 deletion) and 2 DNAs from autistic
patients with a duplication in 10q region. After hybridiza-
tion, ligation and PCR, probes corresponding to the dif-
ferent individuals were electrophoresed and peak
intensities were recorded and blindly analyzed using the
different methods. MLPA hybridization, ligation and PCR
with universal MLPA primers was performed as described
elsewhere [13]. PCR products were loaded on a capillar
DNA analyzer and electrophoresed. Genescan software
was used to analyze the runs and to retrieve peak intensi-
ties corresponding to each probe in the different samples.
Comparison of methods of copy number estimation
Before analyzing the data we illustrate that our proposed
method based on a mixed-model can be applied. Supple-
mentary Figure S1 shows the residual error for each indi-
vidual and probe indicating that the residuals are centered
at zero and that the variability does not change with indi-
viduals. Table 4 shows the results obtained from the 9 test
samples used in the validation study using the threshold,
iterative regression and proposed probe-specific mixed-
model method. For the two patients with Prader-Willi
syndrome, we observed that all methods were able to
detect the three deletions in 15q11-q13 region. The same
conclusion was observed regarding patients diagnosed
with DiGeorge syndrome. Considering patients with
Autism, all methods detected gains in the 10q region.
Only in one case threshold method had a false negative
result and the REX-MLPA method indicated a deletion in
the UBE3A, a false positive finding. These results clearly
agree with our simulation studies in which we found that
iterative regression has a increased type-I error rate and the
threshold approach a low power. For instance, the ratio
between the second individual diagnosed with Autism
and the mean controls was 1.27 at probe named ZWINT,
so the threshold method did not indicate that this was a
probe altered in this individual. This result is due to the
fact that the ratio between the probe-test variability and
the random error variability was around 3 (3.09 = )
and the simulation study showed that in this case the
power of threshold approach is very poor. Finally, regard-
ing HapMap individuals who were considered as negative
controls, we observed that any method found a false pos-
itive result.
Conclusion
The MLPA method is a potentially useful semi-quantita-
tive method to detect copy number alterations in targeted
regions obtained after performing genome-wide screening
0 1423
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hybridization. MLPA is based on comparing peak intensi-
ties of the different probes between test and control sam-
ples through its ratio. Before determining the statistical
significance of dosage ratios, a normalization procedure is
needed to control variation of PCR efficiencies across
probes. We have proposed a non-linear mixed-model to
perform such normalization, and two other existing
methods have been discussed. One of them is based on
considering the sum of peak intensities in each sample,
while another uses internal control probes to fit a regres-
sion line which is used as a reference.
So far, the widely used method to detect statistical signifi-
cance of dosage ratio is to consider as altered those probes
that are outside a given threshold. In this paper, we have
described a new approach to detect altered probes based
on a mixed-model. The threshold is then established by
Table 1: Empirical type-I error and power obtained in 1,000 simulations using the three different approaches: REX (iterative 
regression), PEMM (probe-specific mixture model) and threshold.
Type-I error Power (gains) Power (loses)
σβ σγ σε REX PEMM REX PEMM thres REX PEMM thres
0.2 0.2 0.05 3.7 0.073 0.031 0.815 0.745 0.000 0.819 0.751 0.000
0.2 0.2 0.08 3.6 0.071 0.027 0.689 0.546 0.000 0.681 0.541 0.000
0.2 0.4 0.05 3.5 0.081 0.044 0.923 0.891 0.024 0.930 0.908 0.029
0.2 0.4 0.08 3.5 0.079 0.038 0.870 0.811 0.028 0.863 0.814 0.057
0.2 0.6 0.05 3.6 0.081 0.052 0.965 0.955 0.131 0.956 0.956 0.161
0.2 0.6 0.08 3.6 0.086 0.044 0.922 0.889 0.140 0.922 0.900 0.184
0.2 1.0 0.05 3.6 0.081 0.057 0.980 0.983 0.360 0.977 0.972 0.411
0.2 1.0 0.08 3.6 0.085 0.052 0.955 0.954 0.396 0.947 0.939 0.449
0.2 1.5 0.05 3.6 0.081 0.060 0.982 0.978 0.536 0.981 0.983 0.582
0.2 1.5 0.08 3.6 0.084 0.056 0.981 0.986 0.623 0.980 0.975 0.630
0.2 4.0 0.05 3.5 0.078 0.064 0.995 0.993 0.815 0.993 0.994 0.840
0.2 4.0 0.08 3.5 0.079 0.060 0.996 0.993 0.848 0.993 0.995 0.863
0.4 0.2 0.05 3.7 0.079 0.032 0.822 0.729 0.000 0.827 0.737 0.001
0.4 0.2 0.08 3.7 0.070 0.027 0.690 0.522 0.000 0.697 0.537 0.000
0.4 0.4 0.05 3.7 0.081 0.046 0.918 0.897 0.027 0.926 0.905 0.044
0.4 0.4 0.08 3.7 0.078 0.038 0.878 0.807 0.035 0.871 0.825 0.069
0.4 0.6 0.05 3.6 0.080 0.052 0.958 0.949 0.139 0.952 0.942 0.191
0.4 0.6 0.08 3.5 0.083 0.044 0.926 0.903 0.150 0.913 0.881 0.206
0.4 1.0 0.05 3.7 0.080 0.057 0.981 0.982 0.353 0.973 0.977 0.425
0.4 1.0 0.08 3.5 0.081 0.050 0.949 0.953 0.392 0.950 0.934 0.424
0.4 1.5 0.05 3.6 0.083 0.063 0.989 0.985 0.553 0.987 0.989 0.613
0.4 1.5 0.08 3.6 0.080 0.056 0.976 0.973 0.568 0.966 0.967 0.603
0.4 4.0 0.05 3.6 0.085 0.066 0.997 0.996 0.856 0.995 0.995 0.855
0.4 4.0 0.08 3.6 0.086 0.062 0.994 0.991 0.841 0.989 0.990 0.864
0.6 0.2 0.05 3.6 0.075 0.031 0.828 0.740 0.000 0.824 0.741 0.001
0.6 0.2 0.08 3.6 0.071 0.027 0.701 0.529 0.000 0.690 0.520 0.002
0.6 0.4 0.05 3.7 0.082 0.047 0.932 0.916 0.032 0.914 0.902 0.063
0.6 0.4 0.08 3.6 0.077 0.037 0.864 0.815 0.041 0.874 0.835 0.070
0.6 0.6 0.05 3.7 0.082 0.051 0.964 0.949 0.142 0.955 0.944 0.174
0.6 0.6 0.08 3.6 0.078 0.044 0.924 0.885 0.177 0.918 0.887 0.206
0.6 1.0 0.05 3.6 0.081 0.058 0.977 0.970 0.388 0.972 0.974 0.435
0.6 1.0 0.08 3.6 0.080 0.050 0.946 0.935 0.380 0.960 0.945 0.451
0.6 1.5 0.05 3.6 0.087 0.062 0.982 0.981 0.556 0.982 0.985 0.590
0.6 1.5 0.08 3.6 0.080 0.056 0.972 0.972 0.597 0.975 0.973 0.622
0.6 4.0 0.05 3.5 0.080 0.064 0.995 0.995 0.837 0.994 0.993 0.855
0.6 4.0 0.08 3.6 0.082 0.064 0.988 0.991 0.850 0.990 0.990 0.857
These results are for the case of having 20% of probes as a internal control probes (needed for the REX approach) and 10% of probes as a true 
altered probes. The results are given for different scenarios between probe variability (σβ), probe-test variability (σγ) and within-probe variability 
(σε). The column  indicates the mean number of simulated altered probes.
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cific random error variability observed in each test sam-
ple. We have also discussed another approach based on an
iterative regression. Through simulation studies and a
controlled MLPA assay, we have shown that our proposed
method outperforms the existing ones. Another impor-
tant advantage by comparing our approach and the REX-
MLPA method is that our method can be used even when
no internal control probes are available in the assay.
A novelty of our algorithm is that it can handle informa-
tion from replicate experiments. Replicates of MLPA
assays are typically not necessary for commercial kits since
in most cases more than one probe is used to interrogate
the same region and concordance between those probes is
considered to provide enough reliability of the existence
of a copy number variation. Nevertheless, in cases where
a single probe per region is placed in the assay, it is defi-
nitely useful and desirable (if not necessary) to have rep-
Table 2: Empirical type-I error and power obtained in 1,000 simulations using the three different approaches: REX (iterative 
regression), PEMM (probe-specific mixture model) and threshold.
Type-I error Power (gains) Power (loses)
σβ σγ σε REX PEMM REX PEMM thres REX PEMM thres
0.2 0.2 0.05 3.9 0.044 0.034 0.750 0.765 0.000 0.724 0.747 0.000
0.2 0.2 0.08 3.8 0.043 0.029 0.581 0.584 0.000 0.544 0.564 0.000
0.2 0.4 0.05 4.0 0.048 0.045 0.885 0.919 0.021 0.896 0.922 0.041
0.2 0.4 0.08 3.9 0.049 0.038 0.806 0.827 0.025 0.791 0.820 0.053
0.2 0.6 0.05 4.0 0.054 0.054 0.933 0.954 0.130 0.938 0.957 0.178
0.2 0.6 0.08 4.0 0.051 0.045 0.875 0.903 0.142 0.870 0.888 0.186
0.2 1.0 0.05 3.9 0.053 0.058 0.968 0.976 0.355 0.962 0.978 0.429
0.2 1.0 0.08 4.0 0.045 0.055 0.924 0.954 0.382 0.926 0.954 0.444
0.2 1.5 0.05 4.0 0.047 0.061 0.974 0.983 0.526 0.974 0.986 0.597
0.2 1.5 0.08 4.0 0.052 0.059 0.952 0.971 0.580 0.960 0.974 0.664
0.2 4.0 0.05 3.9 0.053 0.065 0.991 0.993 0.826 0.993 0.997 0.860
0.2 4.0 0.08 4.0 0.049 0.063 0.982 0.990 0.834 0.989 0.993 0.868
0.4 0.2 0.05 4.0 0.044 0.035 0.721 0.754 0.000 0.726 0.752 0.000
0.4 0.2 0.08 3.9 0.045 0.030 0.568 0.544 0.000 0.528 0.550 0.001
0.4 0.4 0.05 3.9 0.048 0.044 0.898 0.912 0.023 0.884 0.919 0.040
0.4 0.4 0.08 4.2 0.050 0.040 0.810 0.823 0.041 0.799 0.830 0.062
0.4 0.6 0.05 4.0 0.047 0.050 0.929 0.945 0.142 0.915 0.940 0.176
0.4 0.6 0.08 4.0 0.046 0.046 0.869 0.895 0.152 0.859 0.894 0.175
0.4 1.0 0.05 4.0 0.051 0.059 0.968 0.983 0.362 0.961 0.976 0.428
0.4 1.0 0.08 3.9 0.050 0.052 0.937 0.956 0.380 0.937 0.951 0.470
0.4 1.5 0.05 4.0 0.049 0.062 0.976 0.981 0.553 0.967 0.978 0.599
0.4 1.5 0.08 4.1 0.050 0.056 0.951 0.969 0.574 0.955 0.971 0.620
0.4 4.0 0.05 3.9 0.047 0.065 0.991 0.995 0.835 0.991 0.997 0.848
0.4 4.0 0.08 4.0 0.050 0.064 0.983 0.988 0.832 0.990 0.997 0.863
0.6 0.2 0.05 4.0 0.045 0.037 0.720 0.748 0.001 0.740 0.775 0.004
0.6 0.2 0.08 4.0 0.044 0.029 0.565 0.584 0.001 0.533 0.572 0.003
0.6 0.4 0.05 4.0 0.051 0.047 0.880 0.896 0.034 0.892 0.915 0.055
0.6 0.4 0.08 4.0 0.047 0.041 0.800 0.824 0.060 0.792 0.818 0.079
0.6 0.6 0.05 4.1 0.051 0.054 0.919 0.938 0.139 0.926 0.947 0.186
0.6 0.6 0.08 3.9 0.047 0.046 0.877 0.893 0.179 0.889 0.924 0.230
0.6 1.0 0.05 4.0 0.050 0.060 0.959 0.976 0.370 0.956 0.971 0.435
0.6 1.0 0.08 4.0 0.048 0.054 0.930 0.947 0.445 0.922 0.948 0.452
0.6 1.5 0.05 4.0 0.049 0.063 0.975 0.983 0.549 0.977 0.985 0.601
0.6 1.5 0.08 3.9 0.049 0.059 0.962 0.973 0.588 0.960 0.965 0.652
0.6 4.0 0.05 3.9 0.053 0.065 0.988 0.993 0.814 0.992 0.994 0.845
0.6 4.0 0.08 3.9 0.055 0.066 0.979 0.987 0.835 0.984 0.995 0.859
These results are for the case of having 10% of probes as a internal control probes (needed for the REX approach) and 10% of probes as a true 
altered probes. The results are given for different scenarios between probe variability (σβ), probe-test variability (σγ) and within-probe variability 
(σε). The column  indicates the mean number of simulated altered probes.
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during the long MLPA protocol and to ensure reliability of
the findings. Thus, having a method that is able to handle
such information is very useful and provides extra statisti-
cal robustness to the findings.
The use of control probes as references for data normali-
zation is one of the methods recommended by the manu-
facturer. Commercial and home-made MLPA assays are
clearly different in terms of quality of the resulting phero-
grams, mainly due to the process of producing the specific
probes that target regions of interest. While commercial
applications produce very high, sharp and neat peaks,
home-made assays typically do not perform that well.
Nevertheless, in both cases, the use of control probes is
always desirable from a statistical point of view and it is so
regardless of the number of probes that target a deter-
mined loci. In exploratory experiments with MLPA
designs targeting extremely variable and polymorphic
CNVs, adding control probes whose behaviour is proven
unvariable and can help in assessing reliability of single
experiments. In such cases, we understand that the inclu-
sion of evenly spaced control probes is a good practice.
One key point is to know the number of replicates that
should be included in a MLPA assay. Our simulations
indicates that 3 replicates was enough to reach a power of
90% keeping a value of alfa around 5% in those combina-
tions where the probe-test variability was over 8 times
greater than that of random error (combinations where σγ
= 0.4 and σε = 0.05). Thus, if the probe-test versus random
error variability ratio was lower, a lesser power would be
expected. In that case the researcher could improve the
expected power by increasing the number of replicates.
Although our proposed method outperforms other exist-
ing ones, it has to be kept in mind that in the case of hav-
ing probes targeting regions that are highly variable
among the population (i.e. in an extreme case where half
individuals are normal homozygous and half are
homozygously deleted), the tolerance intervals calculated
for those probes might collect all existing variability and
become very broad, thus making it impossible to distin-
guish the existence of copy number alteration. Neverthe-
less, the other existing methods would also show
inconsistent copy number calls when analysing such
regions. In statistical terms, this means that we should
have homogeneity of the random error variance through
the probes. This is the reason why a visual inspection of
the pherograms as well as manual curation of the results
might be the most reliable way to proceed. However, we
can easily accomodate cases where the homogeneity of
random error variance assumption cannot be assumed by
introducing an interaction probe-random error allowing a
different random error variance for each probe. In this
case, different tolerance bands would be therefore esti-
mated for each probe.
In conclusion, we have proposed a mixed-model which is
able to determine thresholds to decide whether a region is
altered. These threholds are specific for each individual,
incorporating experimental variability, resulting in
improved sensitivity and specificity as the examples with
real data have revealed. An R language package for the
three approaches discussed in this paper and data ana-
lyzed will be freely available at our web page [25].
Methods
To further illustrate the statistical methods described in
this section, we are using real data provided by the United
Kingdom National Genetics Reference Laboratory of Man-
chester [26]. In particular we are analyzing a dataset from
a breast cancer study (called P002 BRCA1), in which copy
number changes of different genes have previously been
reported. In this example, 9 control probes and 25 analyt-
ical probes were analyzed in a total of 5 controls and 8 dif-
ferent test samples.
Normalization
Herein, we will focus on methods based on considering
the total peak intensities and regression-based
approaches. The first and the simplest method of normal-
ization, determines the normalized signal of each probe
in a given sample by dividing peak intensity by the sum of
all peak intensity of the sample. This method was initially
proposed by [13] and is the recommended method by
MRC-Holland [27] which provides commercial probes for
the copy number analysis of different genome regions for
diagnostic purposes. Let us begin by giving some nota-
tions to illustrate how this method works. Let Hipk be the
peak intensity for the i-th individual, i = 1, ..., C, C + 1, ...,
C + T (C is the number of control samples and T denotes
the number of test samples), the p-th probe, p = 1, ..., P,
and the k-th replicate, k = 1, ..., K. The existing simple
method designed for normalizing data considers the aver-
age of these replicates, , and divides
each measured peak intensity by the sum of all peaks,
 of that sample, i.e. .
In addition to experimental variability, as Figure 1 shows,
peak intensity exhibits a negative correlation with probe
size. To account for this effect, regression methods may be
employed. If internal control probes are provided in the
MLPA experiment (dark vertical lines in Figure 2A), a
regression-based method using the control probes may
also be employed to normalize the data. Different meth-
ods have been proposed. The first approach, known as
"slope correction" [19], model the negative correlation
H H Kip ipkk
K
=
=
∑ /1
S Hi ipp
P
=
=
∑ 1  Y H Sip ip i= /Page 7 of 15
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regression model following the formula ,
where Xpc denotes the size of the pc-th internal control
probe for a given individual (Figure 2B solid blue line), or
using a quadratic model  (Fig-
ure 2B, dotted blue line).
Another possibility proposed by [20] is to fit an exponen-
tial decay model, . In that case, the authors
propose to consider all probes p and call this method
"population normalization". Notice that in that case β
encodes the rate of descend. [20] argued that the trend of
peak intensities varies greatly between samples regarding
the control probes. This is the reason why they propose to
consider all probes (both analytical and control ones)
after applying a median filter approach to remove out-
liers. However this method has important inconven-
iences. The smoothed data, obtained after applying the
median filter, violates some of the assumptions of nonlin-
ear regression such as that residuals are no longer inde-
H Xp pc c= +α β
H X Xp p pc c c= + +α β β1 2 2
Hp
X p
=
−
α
βe
Table 3: MLPA probemix composition
Gene/Region Genomic location Probe size Band Comments
ENm323 chr6:108,723,531–108,723,590 126 6q21 single copy number region
ENm013 chr7:90,250,124–90,250,183 105 7q21.13 single copy number region
ENm014 chr7:126,866,339–126,866,393 99 7q31.33 single copy number region
RNAseP (RPP30) chr10:92,621,710–92,621,757 90 10q23.31 single copy number region
ENr222 chr10:92,621,710–92,621,757 147 6q23.2 single copy number region
ENr111 chr13:29,519,123–29,519,182 123 13q12.3 single copy number region
ENr233 chr15:41,662,068–41,662,127 141 15q15.3 single copy number region
ENm313 chr16:61,141,268–61,141,327 114 16q21 single copy number region
ENr213 chr18:24,170,726–24,170,785 132 18q12.1 single copy number region
RP11–71N21 chr10:51,942,608–51,942,682 144 10q11.23 10q duplication
ZWINT chr10:57,789,521–57,789,580 120 10q21.1 10q duplication
PHYLIP chr10:60,674,910–60,674,995 138 10q21.1 10q duplication
SNRPN chr15:22,764,255–22,764,313 111 15q11.2 15q11 deletion
UBEA3A chr15:23,133,602–23,133,661 129 15q11.2 15q11 deletion
UBE3A chr15:23,171,946–23,171,999 96 15q11.2 15q11 deletion
HIRA chr22:17,698,971–17,699,021 93 22q11.21 22q11 deletion
Table 4: MLPA results from the validation study.
Prader-Willi DiGeorge Autism HapMap
Gene/Region #1 #2 #1 #2 #1 #2 #1 #2 #3
ENm323 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ENm013 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ENm014 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
RNAseP (RPP30) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ENr222 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ENr111 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ENr233 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ENm313 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
ENr213 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
RP11-71N21 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
ZWINT 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0
PHYLIP 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0
SNRPN -1 -1 -1 -1 -1 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
UBEA3A -1 -1 -1 -1 -1 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
UBE3A -1 -1 -1 -1 -1 -1 0 0 0 0 0 0 0 0 0 0 0 -1 0 0 0 0 0 0 0 0 0
HIRA 0 0 0 0 0 0 -1 -1 -1 -1 -1 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
The three colums for each individual indicates the result obtained using mixed-model, threshold and REX-MLPA approaches, respectively. The code 
for the results are the following: -1: relative loss, 0:normal, 1:relative gain. Those result where a disagreement between the three methods is 
observed are in bold face.Page 8 of 15
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[28].
Neither slope correction nor population normalization
approaches consider replicates, e.g. they use  instead
of Hipk. In addition, these methods do not model the var-
iability among individuals either. That is, using these
methods, the authors allow only β to vary among individ-
uals fitting different models for each one. However, the
pattern of decay may vary highly between subjects, which
is not captured by varying β 's only. As an example, the
height of the peak intensity for the first control probe (top
parameter in Figure 2C) and the asymptotic value for
larger probe sizes (bottom parameter in Figure 2C) are
very different among test samples, as we observe in Figure
3.
To circumvent these problems, we propose the following
nonlinear mixed model to normalize the data which
includes replicates and variability among individuals:
Hip
MLPA normalization procedureFigure 2
MLPA normalization procedure. Panel A shows the peak intensities depending on probe sizes. Panel B shows the regres-
sion estimates for different methods: linear regression model using control probes (solid blue line), quadratic model using con-
trol probes (dotted blue line), nonlinear mixed model (red lines) using control probes (solid line) or median filter approach 
(dotted line). Panel C illustrates the parameters involved in the nonlinear mixed model. Panel D shows the size-adjusted nor-
malized peak intensities prepared to compute the dosage quotient. In all panels dark lines represents control probes while light 
lines are for analytical probes.Page 9 of 15
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BMC Bioinformatics 2008, 9:261 http://www.biomedcentral.com/1471-2105/9/261Regression estimates for the test samples from BRCA1 data setFigure 3
Regression estimates for the test samples from BRCA1 data set. Regression estimates for each of the 8 test samples 
given in the example provided by the NGRL-Manchester called P002 BRCA1. Red lines are estimated using the nonlinear 
mixed model. The solid lines are estimated using control probes, while dotted lines are obtained after using the median filter 
approach. The dotted blue lines are showing the regression estimates using quadratic model. These regression lines are then 
used to normalize the peak intensities.
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BMC Bioinformatics 2008, 9:261 http://www.biomedcentral.com/1471-2105/9/261where Xp denotes the size for the p-th probe (note that it
only depends on the probe since it is the same for each
individual and each replicate) φi1 is the maximum peak
intensity for control probes, φ2i, is the asymptotic peak
intensity, and φ3i is the reciprocal of the rate decay con-
stant. The term offi provides a more stable parametriza-
tion for the data and corresponds to the average value of
the peak size for the first control probe, offi = ,
i = 1, ..., C, C + 1, ..., C + T. The fixed effects, β represent
the population average of subject-specific parameters, φi,
and the random effects, bi, represents the deviations of the
φi's from their population average. The random effects are
assumed to be independent and the within-group errors
εipk are assumed to be independent for different i, p and to
be independent of the random effects. The model param-
eters are fitted by maximizing the restricted log-likelihood
(RMLE) of the data using the R library nlme [29].
After estimating this generalized exponential model, the
normalization procedure is performed by dividing the
peak intensities, Hipk, by the regression estimate, ,
obtaining a normalized, size-adjusted peak intensity for
every probe, Yipk = Hipk  (Figure 2D). For the control
samples we consider a unique regression line correspond-
ing to the average of all control samples. Nonetheless, for
the test samples the normalization is performed individu-
ally for each subject.
Statistical significance of dosage ratios
Ratio approach
The normalized peak intensities may be directly com-
pared between control and test samples peak by peak. The
first method for determining genes that are altered (gains
or loses) is based on a threshold rule. The probes whose
dosage ratios are outside of the threshold lines are consid-
ered altered. The thresholds are normally 0.7 for deletions
(note that 0.5 would correspond to a half reduction in the
dosage but this value is considered too stringent by some
researchers) and 1.33 for duplications, although other
cut-points have been used in other studies [18].
Iterative regression
The main disadvantage of defining a threshold is that the
specific variability of each experiment is not considered.
Some authors have proposed alternative methods using
linear regression models. [19] stated that, after a square-
root transformation of the data, the plot of normalized
peak intensities for test samples versus control samples
should be around the diagonal if no dosage imbalances
are present; otherwise, probes above or below would cor-
respond to duplications or deletions, respectively. Their
proposal was to fit a linear regression without intercept
using only control probes and use the standard error of
the regression to determine confidence limits for outlier
detections. As in the case of normalization procedures,
however, a small number of control probes is a limiting
factor for adopting this approach since, as the author
stated, the standard error of the regression underestimates
the normal variability. Thus, [19] proposed an iterative
H
i
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Normal control comparison procedure using iterative reg essionFi ure 4
Normal control comparison procedure using itera-
tive regression. Plot of normalized peak intensities in con-
trols (calculated as the mean of all controls) against 
normalized peak intensities in test sample number 1 using 
iterative regression procedure. Dotted line correspond to 
linear regression among those probes that are considered 
non altered after applying the iterative procedure. Solid lines 
determine upper and lower boundaries which are used to 
indicate whether or not a given probe is a duplication or a 
deletion, respectively.
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BMC Bioinformatics 2008, 9:261 http://www.biomedcentral.com/1471-2105/9/261regression algorithm for this problem. Starting with the
control probes, the linear regression is fitted. Then, a pre-
diction interval is computed for every probe. If the nor-
malized peak intensity of a non-control probe falls into
this interval, the probe is considered to belong to the non-
altered population and it is added to the control probes in
the next step. After a few iterations, a final model is
reached including only those probes that are considered
as preserved. In practice, those probes that are not
included in this final model are considered to be either
Normal control comparison procedure using tolerance interval criteriaFigure 5
Normal control comparison procedure using tolerance interval criteria. Plot of ratio between normalized peak 
intensities in controls against normalized peak intensities in each of the 8 test samples (vertical lines). Horizontal gray lines indi-
cate lower and upper boundaries obtained using the linear mixed model and tolerance interval criteria. Vertical green lines are 
indicating that those probes are duplicated for the corresponding probe.
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BMC Bioinformatics 2008, 9:261 http://www.biomedcentral.com/1471-2105/9/261deleted or duplicated. The authors call this method
Regression-Enhanced MLPA analysis (REX-MLPA). Figure
4 illustrates the confidence limits of the final regression
model. [20] proposed a similar approach but starting with
all probes and retaining and rejecting points at each itera-
tion with a given level of confidence.
The REX-MLPA approach assumes that the X variable (e.g.
squared-root of mean normalized peak intensities in con-
trols) in the linear regression model is measured without
error. This assumption is not tenable since this variable
corresponds to the normalized peak intensity measured in
multiple control samples. Violations of this assumption
are a serious problem when trying to accurately predict Y
(squared-root of normalized peak intensities in test sam-
ple) from X.
The probe-specific mixture model
The REX-MLPA approach has the limitations discussed
above, specifically, the regression models are fitted with-
out considering that the independent variable (normal-
ized peak intensity in controls) is also subject to error. In
addition, confidence intervals for predictions are built
assuming the normal theory. This assumption may not
hold when only control probes are considered since we
typically have no more than 10 probes. Replicates for each
individual are also not considered.
Based on these limitations, we propose the following
model to compare controls with a given test sample:
where μ is the mean normalized peak intensity across
individuals and probes, αt is a fixed effect representing a
different mean for all controls (t = 0) and a given test sam-
ple (t = 1), βp is a random effect for the pth probe, γtp is is
the probe-test interaction random effect, and εtpk is a ran-
dom error variable. The index p denotes the probe, and K
is the number of replicates. We assume that βp, γtp, and εtpk
are independent, homocedastic, and normally distributed
random variables with mean zero. The variances are
denoted by  for the, βp, or the "between-probe" varia-
bility,  for γtp, or "probe-test" variability, and  for
the εtpk, or "within-probe" variability. Considering the
assumptions of the proposed model, we need to verify
that the within-groups errors are independent and identi-
cally normally distributed, with mean zero and variance
, and that they are also independent of the random
effect. It can be easily checked using different plots. This
assumption makes sense for biologists since probes that
behave abnormally in replicate studies or when hybrid-
ised onto DNAs that have a different quality are typically
removed or redesigned to ensure assay robutness and reli-
ability. The model parameters are fitted by maximizing
the restricted log-likelihood (RMLE) using the R library
lme (Pinheiro and Bates, 2000).
The criterion
For the sake of simplicity, we take control samples as the
reference, i.e. α0 = 0 and α1 = α, and γ0p = 0. Therefore, α
may be interpreted as an average deviation between test
and control samples across all probes, and γ1p as the devi-
ation control-test for the p-th probe.
The criterion to determine those probes that are altered
for each test sample is based on the observed differences
among controls and its differences with controls samples.
Conditioned to p-th probe, the difference between two
control measurements is distributed as
Conversely, the difference between a test, i', and a control
sample, conditioned to a given probe, is distributed as
where  corresponds to the variance of the error defined
in equation (2). Then, we consider that a probe is not
altered if the mean of the difference between test and con-
trol samples is included within a probability interval
defined by differences between control samples distribu-
tion. Hence, the criterion consists in checking whether the
difference between test and control samples is greater than
that expected between two control samples. That is,
whether the difference is included in the interval
where Z1-κ/2 is the 1 - κ/2 percentile from the standard nor-
mal distribution. Hence, 1 - κ is the proportion of differ-
ence control-control that the difference test-control must
exceed to declare that a probe is altered. Nonetheless,
when using sample data to estimate such intervals, the
uncertainty associated with the estimation estimating
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BMC Bioinformatics 2008, 9:261 http://www.biomedcentral.com/1471-2105/9/261them has to be considered. Therefore, we propose to esti-
mate the interval (5) through a tolerance interval over the
control-control differences distribution. To build such
intervals, it is assumed that , where ν are the
residual degrees of freedom, and  is the REML estima-
tor of . Therefore, the tolerance interval that contains
(1 - κ)% proportion of the control-control differences esti-
mated with a confidence of (1 - α)% is
Once the limits of the criterion are established, the mean
difference test-control, δp for each probe, p, is estimated
using the estimate of α + γi'p, where γp1 is estimated
through the best linear unbiased predictor (BLUP). Then
a probe for a given test sample is considered as altered
when δp does not fall into (6). Figure 5 shows those probes
that are imbalanced for each individual considering the
threshold obtained using tolerance limits obtained using
equation (6). In this example those limits are 0.78 for
deletions and 1.29 for duplications.
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